| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 5, 2013New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently
MINNEAPOLIS - March 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of...
-
Feb 19, 2013Revenue of $4.0 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS - February 19, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2013, which ended January 25, 2013. The Company reported...
-
Feb 13, 2013Second-generation MR-Conditional Pacemaker Combines Advanced Pacing Technology with MRI Access
MINNEAPOLIS - February 13, 2013 - Showcasing its leadership position in pacing technologies, Medtronic, Inc. (NYSE: MDT), today announced the U.S. Food and Drug Administration (FDA) approval and...
-
Feb 3, 2013Rubio Helps Web Visitors Save a "Virtual" Life at HeartRescueNow.com
MINNEAPOLIS, February 5, 2013 -Minnesota Timberwolves basketball star Ricky Rubio joins the Medtronic Foundation this February in saving young lives worldwide from sudden cardiac arrest (SCA)....
-
Jan 24, 2013Self-Expanding Peripheral Device Gets CE Mark for Superficial Femoral and Proximal Popliteal Arteries
MINNEAPOLIS -- Jan. 24, 2013 -- Expanding its role in the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the CE (Conformité Européene) mark and international...
-
Jan 15, 2013Second-Generation Sheath May Facilitate Easier Access to the Inferior Veins When Treating Paroxysmal Atrial Fibrillation
MINNEAPOLIS - Jan. 15, 2013 - Medtronic, Inc. (NYSE: MDT) today announced Food and Drug Administration (FDA) clearance and U.S. launch of the FlexCath Advance(TM) Steerable Sheath, a new...
-
Dec 17, 2012Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months
MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
-
Dec 6, 2012
MEMPHIS, Tenn. - Dec. 6, 2012 - Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced the U.S. launch of the company's latest addition to their cervical surgical technique...
-
Nov 20, 2012Revenue of $4.1 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - November 20, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2013, which ended October 26, 2012. The Company reported...
-
Sep 12, 2012Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People
MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...